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Abstract
Background: Adherence is one of the most important determinants of viral suppression and drug resistance in
HIV-infected people receiving antiretroviral therapy (ART).
Methods: We examined the association between long-term mortality and poor adherence to ART in DART trial
participants in Uganda and Zimbabwe randomly assigned to receive laboratory and clinical monitoring (LCM), or
clinically driven monitoring (CDM). Since over 50% of all deaths in the DART trial occurred during the first year on ART,
we focussed on participants continuing ART for 12 months to investigate the implications of longer-term adherence
to treatment on mortality. Participants’ ART adherence was assessed by pill counts and structured questionnaires at
4-weekly clinic visits. We studied the effect of recent adherence history on the risk of death at the individual level
(odds ratios from dynamic logistic regression model), and on mortality at the population level (population attributable
fraction based on this model). Analyses were conducted separately for both randomization groups, adjusted for
relevant confounding factors. Adherence behaviour was also confounded by a partial factorial randomization
comparing structured treatment interruptions (STI) with continuous ART (CT).
Results: In the CDM arm a significant association was found between poor adherence to ART in the previous 3-9
months with increased mortality risk. In the LCM arm the association was not significant. The odds ratios for mortality
in participants with poor adherence against those with optimal adherence was 1.30 (95% CI 0.78,2.10) in the LCM arm
and 2.18 (1.47,3.22) in the CDM arm. The estimated proportions of deaths that could have been avoided with optimal
adherence (population attributable fraction) in the LCM and CDM groups during the 5 years follow-up period were
16.0% (95% CI 0.7%,31.6%) and 33.1% (20.5%,44.8%), correspondingly.
Conclusions: Recurrent poor adherence determined even through simple measures is associated with high
mortality both at individual level as well as at the ART programme level. The number of lives saved through effective
interventions to improve adherence could be considerable particularly for individuals monitored without using CD4
cell counts. The findings have important implications for clinical practice and for developing interventions to enhance
adherence.
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Background
Adherence is one of the most important determinants
of viral suppression among people receiving antiretro-
viral therapy (ART) for HIV-infection; conversely poor
adherence is associated with acquired antiretroviral drug
resistance [1-4]. Adherence measurements and methods
for summarizing adherence vary depending on resources,
with some researchers showing that adherence may be
seen as a stochastic process [5-7]. Adherence has been
measured using different indices such as drug posses-
sion ratio [8], or simple proportions or counts of missed
pills/appointments [8-11], or measured using electronic
medication monitors [12]. Although good adherence is
essential for the success of ART, there is no gold standard
or benchmark measure of adherence. However, electronic
monitoring of adherence was more strongly associated
with viraemia compared to self-reported adherence mon-
itoring [13,14]. Other studies did not show any dif-
ference between adherence measures and viral load
suppression [15].
For HIV-infected adults, poor adherence leads to
low levels of drug, leading to viral replication, drug
resistance, and viral rebound. That in turn causes
CD4 decline which leads to morbidity/mortality. Sev-
eral studies have demonstrated the association between
adherence and mortality [16,17]. However, factors includ-
ing drug toxicity/side effects, resistance, disease stage
and sociodemographic factors may be associated with
both adherence and mortality either being on the
causal pathway between adherence and mortality (as
intermediate factors), or as a proxy for some unmea-
sured confounding depending on the time order of the
events.
Many studies [18] have identified prognostic factors for
mortality following ART initiation; the most recent val-
ues of immunological and virological factors are typically
the most predictive. In contrast a single report of poor
adherence may not be associated with immediate mor-
tality, but rather recurrent poor adherence, i.e. adherence
history, may be the main driver of longer-term mortal-
ity. Dynamic logistic regression can be used to examine
the delayed effect of predictors on death, which may be
seen several months after the reported poor adherence, in
a similar way to a time-dependent Cox model. However,
the advantage of dynamic logistic regression is that it eas-
ily allows estimation of the achievable effects of risk factor
manipulation at the population level, i.e. the proportion
of deaths that could have been avoided with optimal
adherence.
Here we examine the association between mor-
tality and adherence to ART using data from the
DART (Development of AntiRetroviral Therapy) trial in
Uganda/Zimbabwe [19], in which participants were ran-
domly assigned to laboratory and clinical monitoring
(LCM) or clinically driven monitoring (CDM) of ART.
Our main aim was to investigate the effect of adherence
history on the risk of death in the second year on ART
onwards at the individual level (odds ratios, OR) and at the
population level (population attributable fraction, PAF).
We also assess the time delay in the effect of adherence on
the risk of mortality. Over 50% of all deaths in the DART
trial occurred during the first year on ART, when the risk
of death is higher, and mortality may be less influenced by
adherence [19,20]. In this paper we focussed on partici-
pants surviving the first year of ART, in order to investi-
gate the impact of longer-term adherence to treatment on
mortality.
Methods
Data and problem
Study population
3316 ART-naive adults with symptomatic HIV disease
and CD4<200 cells/μL were enrolled in the DART
trial January 2003-October 2004 at three centers, 2 in
Uganda (and 1 satellite) and 1 in Zimbabwe, and ini-
tiated triple drug ART [19]. 2469(74%) received com-
bivir (coformulated zidovudine-lamivudine) and tenofovir
disoproxil fumarate, 300 received combivir and abacavir,
and 547 received combivir and nevirapine as their first-
line ART. Participants were randomly assigned to labo-
ratory and clinical monitoring (LCM) or clinically driven
monitoring (CDM); both groups saw a physician and
had a routine full blood count with lymphocyte sub-
set CD4 every 12 weeks, but total lymphocyte or CD4-
cell counts were not returned for the latter group. All
participants were reviewed by a nurse every 4 weeks
(using a standard symptom checklist) and had 4-weekly
ART refills.
Adherence behaviour was potentially confounded by a
further partial factorial randomization comparing struc-
tured treatment interruptions (STIs, cycles of 12 weeks
on/off ART) with continuous ART (CT) in participants
with good early response (CD4>300 cells/μL) at the week
48 or 72 CD4 count [21] (This followed a small pilot study
in 137 patients; these pilot patients were excluded from
all analyses). The CT/STI randomizations were stopped
early, in March 2006, due to inferiority of STIs, and all
patients randomized to STIs returned to continuous treat-
ment. (See Figure 1.) The potential confounding effect
of STI is addressed in the model in the following way:
In our dynamic modeling, the effect of adherence on
mortality is obviously not confounded by the STI group
before the randomization. After the randomization the
individuals randomized to the STI group are parame-
terized as a separate group from those remaining on
continuous therapy with known adherence behaviour, and
therefore they do not confound the main effect of adher-
ence on mortality after the randomization either. We do
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not wish to censor these individuals at the time of STI
randomization as they may still carry information about
the connection between other explanatory variables and
mortality.
Participants were followed under their randomized
strategies until December 31, 2008. More than 50% of
the total deaths over a median 5 years follow-up in
DART occurred during the first year on ART, >25%
in the first 3 months [20]. These deaths in the first
year on ART are plausibly due to carryover effects from
the advanced immunosuppression prior to at ART ini-
tiation (ART cannot work fast enough) and therefore
are less likely to be related to ART adherence. Includ-
ing these deaths in analysis may therefore dilute the
impact of adherence over the longer-term. As our focus
was on the impact of adherence on longer-term mor-
tality on ART, we therefore excluded the 171 partici-
pants that died and the 48 lost to follow-up during the
first year on ART, leaving 2960 participants alive and in
follow-up at one year for analysis, the same dataset as
previous analysis [7,22]. This allowed us to investigate
adherence history measures based on up to 12 previous
visits.
Informed consent
Individual informed consent was obtained from each par-
ticipant at screening and, if eligible, at enrolment for
randomisation to (i) the two monitoring strategies (LCM,
CDM)(all participants) and (ii) STI or CT if eligible.
Ethics statement and approval
DART received ethics committee approval in Uganda
from the Science and Ethics Committee (SEC), in
Zimbabwe from Medical Research Council of Zimbabwe
(MRCZ) which is the National Ethics Committee (NEC)
and the Imperial College Research Ethics committee in
the UK. The trial was registered (ISCRTN13968779).
Adherencemeasurements
Participants’ ART adherence was assessed by pill counts
and a structured questionnaire administered at each
scheduled 4-weekly clinic visit [23]. The questionnaire
asked whether they had missed any doses in the last
month, were late for the visit, had forgotten to take any
doses at the weekend, or missed any ART on the previ-
ous 4 days. Adherence data is missing if (i) the participant
missed his/her visit (“missing”), or if (ii) the participant
attended the visit but did not, for some unknown rea-
son, respond to these questions (“non-response”). We
consider patients who had been randomized to STI as
an additional class of missing (ie as a separate group),
since their adherence measurements and outcomes may
no longer be directly comparable with those taking ART
continuously.
Outcome and problem
Our primary outcome is mortality in those surviv-
ing the first year on ART, censored at the mini-
mum of their last follow-up visit or 31 December
2008. We model the effect of adherence history on
the risk of death at the individual level (odds ratios
from a fitted dynamic logistic regression model) and
at the population level (population attributable fraction,
PAF) using the estimated model parameters. We also
assess the time delay in the effect of adherence on
the risk of mortality. As the main trial results demon-
strated a small but statistically significant difference in
mortality between the LCM and CDM groups [19],
analyses were done separately for both groups, and
estimates adjusted for relevant pre-ART confounding
factors.
Statistical methods
Dynamic logistic regressionmodel
The data are analyzed using a dynamic logistic regres-
sion model. The follow-up period of each individual is
divided into successive 4-weekly periods between the
clinic visits. Then the probability of dying in a cer-
tain period is the probability of surviving previous peri-
ods multiplied by the conditional probability of dying
in that period conditional on previous survival. The
model is then the regular logistic model for these con-
ditional probabilities and the explanatory variables for
death in a period may include any variables describ-
ing the individual’s history up to the beginning of
the period. The odds ratios are then for the instanta-
neous risk of dying in a period. The model may be
seen as a discrete time version of the Cox’s propor-
tional hazard model (details given in Additional file 1:
appendix A).
Population attributable fraction (PAF)
The estimated model is used to find an estimate for
population attributable fraction as follows. For each indi-
vidual with known covariate history, one can, with an
estimated model, estimate the probabilities of dying
on each 4-weekly interval in an imaginary case of
his or her optimal adherence. If this is done sepa-
rately for each individual in a population, the results
can be summarised at the population level as a sur-
vival curve for an imaginary population of patients
with optimal adherence. If this curve is compared
to the observed overall survival curve (or the curve
without the manipulation), one can calculate an esti-
mate for the proportion of deaths that could have
been avoided by manipulation, that is, the popula-
tion attributable fraction of deaths due to non-optimal
adherence. (See Additional file 2: appendix B for
more details).
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Figure 1 Illustration of the first and second randomization of the participants of the DART trial (356 died/lost to follow-up or excluded in
first year). The latter confounds adherence measurements: 813 good early response participants were randomized between continuous therapy
(CT) and cycles of 12 weeks on/off ART structured treatment interruptions (STI). We analysed all participants alive and in follow-up at 48 weeks.
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Summarising adherence history (x1)
Here we use the 4-weekly question “missed a dose in the
last month”, because it was most strongly associated with
viral load [23]. At each visit t = 1, 2, ... the adherence
variable can take the following four values
“poor”, “good”, “non-response”, and “missing”,
where “poor” and “good” mean “missed a dose in the
last month” and “did not miss a dose in the last month”,
respectively.
The history of adherence behaviour up to the visit t is
then summarized as follows. First, we consider the visits
t − 8, t − 7, ..., t − 3 (6 visits, that is, 6 months) to calculate
the following three independent indicator variables
“poor at least once”, “non-response at least once”,
“missing at least once”,
for visits t. These three adherence variables are not mutu-
ally exclusive, that is, any combination of zeros and ones is
possible. Whilst this is only one way to combine 4-weekly
adherence measurements, it is a simple summary which
retains much of the historical information. As a delay in
the effect of adherence on mortality is likely given the
causal pathway (see above), we used adherence data from
visits t − 8, t − 7, ..., t − 3 only to predict the mortality
between visits t − 1 and t. The adherence measurements
at visits t − 2 and t − 1 may then be seen rather as inter-
mediate factors between adherence history and death.
In fact, preliminary analysis showed that patients dying
between visits t − 1 and t often missed visits t − 2 and
t − 1 for reasons that were clearly more related to their
mortality risk than their adherence behaviour. Whilst sev-
eral other time intervals t − u, ..., t − v were considered,
we presented results only for t − 8, t − 7, ..., t − 3 as
the associations with mortality were generally very sim-
ilar. One can naturally also try other time intervals t −
u, ..., t − v with different choices of u and v but then
the incidence and interpretation of “poor at least once”,
for example depends strongly on the length u − v + 1.
The comparison of different fitted models is therefore
difficult, and we tried to keep the model as simple as
possible.
The adherence measurement are, however, confounded
by the CT/STI randomization as explained above. We
therefore need a fourth indicator
“randomized to STI”
which is 1 at visit t if the patient has been randomized
to STI before visit t. If 1, then the three adherence indi-
cators above lose their interpretation and are all set to
be 0. Essentially therefore after having been randomised
to STI, patients are modelled separately both in terms
of their subsequent on-ART adherence and its relation-
ship to mortality. If all four indicators get the value zero,
then the patient is not randomized to STI and adherence
behaviour is “optimal”; this is thus the reference class in
the modeling.
Confounding variables (x2)
We fitted an adjusted model including the following
fixed pre-ART characteristics: age (18-35, 35-50, 50+),
sex (male, female), WHO disease stage (2, 3, 4), body
mass index (BMI) (-20, 20-27, 27+), and CD4 cell count
(0-49, 50-99, 100-149, 150-199), categorizing continuous
variables to allow for non-linearity.
We did not treat, for example, time-dependent CD4
cell count as a confounding variable. We rather consid-
ered it as an intermediate variable, meaning that CD4
cell count at time t is likely affected by previous adher-
ence history, and is simultaneously a subsequent predictor
of mortality. For this reason, only pre-ART CD4 count
was included as a baseline factor (similarly for WHO
disease stage and BMI). Although follow-up and adher-
ence history in this study starts at 12 months, we did
not adjust for CD4 count 12 months after starting ART
for the same reason, namely adherence behaviour dur-
ing the first 12 months could have already had an impact
on CD4, which in turn would have an effect on mortal-
ity. The main exposure of interest is adherence history
and adherence measurements were taken on the preced-
ing nine months in our analysis (ie adherence history from
3-9 months on ART for the first interval). To adjust for
the effect of time on ART, we included a variable follow-
up time, categorized as (1,2], (2,3], (3,4], (4,5], and (5,6]
years on ART.
Results
Mortality risk at individual level
Median (IQR) follow-up after 1 year on ART in the 2960
patients surviving 12 months was a further 3.9 (3.5-4.3)
years on ART, see Table 1. The proportion of individuals
reporting good adherence at each visit remained very high
and stable over most of the five year period (Figure 2 and
Figure 3), with little difference in the adherence profiles
between the LCM and CDM groups. However, the num-
ber of missing visits did increase with time, at least in part
because, after approximately 3 years on ART, a small num-
ber of participants moved to 12-weekly visits, with tele-
phone nurse visits in-between (without adherence data).
This may result in a small bias in the estimates of the effect
of missing visits on mortality.
As previously reported [19], patients randomized to
CDM had a higher mortality risk than LCM patients with
an unadjusted odds ratio 1.56 (95% CI 1.17,2.08) after the
first year on ART.We therefore did the analyses separately
for both groups.
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Table 1 Characteristics of ART naive adults initiating ART
in Uganda and Zimbabwe and surviving the first year of
Therapy bymain randomisation arm
Baseline characteristics at
randomisation and week 48
Randomisation in main DART trial LCM CDM
Total participants 1478 1482
Sex
Female 970(66%) 952(64%)
WHO stage
2 331(22%) 291(20%)
3 827(56%) 844(57%)
4 320(22%) 345(23%)
BMI
< 20 489(33%) 515(35%)
20-27 846(58%) 831(56%)
>27 130(9%) 127(9%)
CD4 cells/μL
Median (IQR) 84(33-138) 86(31-140)
Age(years) at ART initiation
Median (IQR) 37(32-42) 36(32-42)
18-35 589(40%) 593(40%)
35-50 792(54%) 796(54%)
>50 97(6%) 93(6%)
Initial ART regimen
Tenofovir (TDF) 1075(73%) 1087(73%)
Nevirapine (NVP) 260(18%) 251(17%)
Abacavir (ABC) 143(10%) 142(10%)
Follow up at 48 weeks
STI/CT randomisation
Not randomised 1061(72%) 1082(73%)
Randomised to STI 209(14%) 203(14%)
Randomised to CT 208(14%) 197(13%)
CD4 cells/μL at week 48
Median (IQR) 201(139-283) 200(141-280)
Weight at week 48
Median(IQR) 63(57-71) 63(56-71)
The estimated odds ratios (OR) with 95% CI for differ-
ent risk factors for mortality from the dynamic logistic
model in LCM and CDM groups are given in Tables 2
and 3, respectively, and demonstrate a clear association
between poorer adherence and 4-weekly probability of
dying in the CDM group. In the LCM group the differ-
ence in mortality risk between poor and optimal adherers
was in the same direction but was non-significant. The
adjusted odds ratios (with p values) for “poor at least
once vs. optimal”, “non-response at least once vs. opti-
mal” and “missing at least once vs. optimal” were 1.30
(0.3), 1.98 (0.03) and 3.60 (<0.001) in the LCM group
and 2.18 (<0.001), 2.09 (<0.001) and 3.65 (0.005) in the
CDM group. The largest differences between LCM and
CDM groups can be seen in the odds ratios for poor
vs. optimal (1.30 and 2.18 for LCM and CDM groups,
correspondingly). However, 95% CI were relatively wide,
and fitting both groups together in a single model, a
heterogeneity test did not provide evidence of differ-
ence (p>0.1). There was strong evidence of heterogeneity
in the 3 adherence estimates within each model ie the
impact of poor adherence on mortality risk differs from
impact of non-response differs from the impact of missing
(p <0.001). The adjusted odds ratios for “having pre-
viously been randomized to STI vs. optimal” (technical
indicator that at least partially addresses confounding by
the CT/STI randomization) in the LCM and CDM groups
were 0.86 (0.29, 2.05) and 2.07 (1.03, 3.85). This indicates
that over the longer-term those previously undergoing
STIs in the CDM group still had poorer outcomes, likely
due to delays in identifying first-line drug failure in the
CDM group [19].
For those monitored following LCM, mortality risks
seemed somewhat lower at visits either 2-3 or 4-5 years
on ART (p=0.06), none of the other pre-ART factors
were significantly associated with mortality risk after 1
year on ART (p>0.3). In contrast, in the CDM group the
post-1-year mortality risks were higher for patients with
pre-ART <150 cells/μL (p=0.01 for categorical pre-ART
CD4 variable), and for patients aged >50 years at ART
initiation (p=0.07 for categorical variable age). There was
no additional effect of regimen at ART initiation with the
adjusted OR for Nevirapine, Abacavir versus Tenofovir
1.18 (0.61, 2.12), 1.21(0.52, 2.45), p=0.8 in LCM and 0.52
(0.25, 0.96), 0.64 (0.28, 1.24), p=0.1 in CDM. All these
results were consistent with themain trial results of DART
[19], which showed that differences in mortality between
LCM and CDM were most likely due to delayed switch-
ing (for failure of first-line to second-line treatment) in
the latter group without CD4 count monitoring. Low pre-
ART CD4 and higher age have been previously identified
as factors which increase the risk of ART failure.We found
no evidence that the impact of current adherence varied
according to pre-ART CD4 (p=0.4).
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Figure 2 Proportion of participants at weeks t = 52, 56, 60, . . . on ART in the LCM group who (i) miss a visit (solid circle curve) (ii) miss a
visit or do not respond to the adherence question (diamond symbol curve), (iii) miss a visit, do not respond, or report poor adherence
(square symbol curve). The periodicity in the curves after 3 years is partly due to a small group of patients who moved to 12-weekly ART refills and
therefore missed intervening 4-weekly visits.
To consider the bias caused by the participants who
moved to 12-weekly visits (with telephone nurse visits
in-between), we also fitted interactions between time
indicator (4,6] and adherence variables. There was no
statistically significant interactions in the LCMgroup. The
only statistically significant interaction term (p=0.004) in
the CDM group was for the interaction between non-
response and time. The adjusted odds ratio for non-
response vs. optimal then changed from 3.72(95% CI
2.07,6.35) to 0.10(95% CI 0.01,0.38). This change may be
due to the fact that the subjects with 12-weekly visits
are classified as non-responders but in fact they are good
adherers and therefore eligible for 12-weekly refills. In fur-
ther analyses, we also considered censoring individuals
with 12 weekly telephone visits from the 4th year. The esti-
mates for the main exposure adherence variables and PAF
censoring the 12-weekly telephone visits were very similar
to the analysis including these participants in both LCM
and CDM groups.
Population attributable fraction
In Figure 4 estimated survival curves are shown in the
LCM and CDM groups. In both groups, we calculated
a weighted Kaplan-Maier survival curve estimate for
the original population assuming all patients had been
intended to take ART continuously (ie if the CT/STI
randomization had not occurred), by using weights 2
and 0 for those randomized to CT and STI respectively
(after randomization), and 1 for non-randomized patients
(and before STI/CT randomisation). Then we used the
model-based hypothetical estimated survival curves for
the same population but with optimal adherence his-
tory (all four indicators constantly zero, confounded vari-
ables as in the population) were calculated. The PAF
estimates are then based on the values of these curves
at 5 years.
The estimated proportion of deaths that could have
been delayed (by eliminating exposure to non-optimal
adherence) 1-6 years after initiating ART was 16.0%
among patients receiving LCM, but was higher at 33.1%
in CDM. The corresponding 90% confidence intervals
based on 200 bootstrap samples were (-0.7%,31.6%)
and (20.5%,44.8%), respectively. These proportions cor-
respond to absolute increases in 6-year survival (5 years
after our 48 week baseline) of 1% in the LCM group (from
94% observed to 95% with optimal adherence) and 3% in
the CDM group (from 91% observed to 94% with optimal
adherence), with corresponding death rates from 1.2/100
to 1/100 person years in LCM and 1.8/100 to 1.2/100
person years in CDM.
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Figure 3 Proportion of participants at weeks t = 52, 56, 60, . . . on ART in the CDM group who (i) miss a visit (solid circle curve) (ii) miss a
visit or do not respond to the adherence question (diamond symbol curve), (iii) miss a visit, do not respond, or report poor adherence
(square symbol curve). The periodicity in the curves after 3 years is partly due to a small group of patients who moved to 12-weekly ART refills and
therefore missed intervening 4-weekly visits.
Discussion
The results of this study emphasize the importance of
ART adherence for reducing long-term mortality risk in
HIV-infected adults taking ART. Three measures of non-
optimal adherence, missing a dose, not responding to the
adherence questionnaire, and missing a visit at least once
during a preceding 6 month period, independently pre-
dicted increased immediate mortality risk in patients only
monitored using clinical symptoms in the DART trial in
Uganda and Zimbabwe, with the latter two measures also
predictive in patients being monitored using CD4 cell
counts. There was strong evidence within each model
that the impact of poor adherence on long-term mortal-
ity risk differs from non-response, and differs from those
with missing response. These effects were independent
of potential pre-ART confounders WHO disease stage,
CD4 cell counts, body mass index, age, and sex, and time-
dependent STI group and time on ART. Whilst there was
a non-significant trend towards a larger effect of poor
adherence in the group of participants monitored without
CD4 cell counts, perhaps the most important finding was
that optimal adherence with clinical monitoring seemed
to provide as good overall survival outcomes as those
actually observed in the group receiving CD4 monitoring
in the trial (Figure 4).
Although the survival under optimal adherence is
unknown in this context, the major advantage of the
dynamic logistic regression model is that it can be esti-
mated. Only modest absolute differences in mortality risk
were observed (1% in LCM and 3% in CDM at 6 years
from ART initiation) , but the estimated proportions
of deaths that could have been delayed (by eliminating
non-optimal adherence) within 1-6 years after initiating
ART were remarkably high in both groups - 16% in the
LCM and 33% in CDM. This equates to absolute increases
in 6-year survival from 94% observed to 95% with opti-
mal adherence in LCM and from 91% observed to 94%
in CDM. The differences in estimated mortality between
LCM and CDM under optimal adherence were narrower
than observed in the trial itself, suggesting that, as well
as its role in detecting ART failure earlier, one major role
of CD4 monitoring could be to to reinforce good adher-
ence behaviour, or to identify those with adherence issues.
This may be particularly valuable if laboratory moni-
toring can be integrated with adherence data to focus
interventions on priority patients who need more sup-
port. However, too few deaths were observed to rule out
the possibility that differences in associations between
adherence and mortality in LCM and CDM were due to
chance alone.
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Table 2 Estimated unadjusted and adjusted odds ratios (OR) with 95 percent confident intervals for the risk of death
obtained from the dynamic logistic regressionmodel and based on 1478 individuals in the LCM group alive after the first
year of follow-up
Unadjusted OR 95% CI Adjusted OR 95% CI P-value
Adherence history:
poor at least once vs optimal 1.34 (0.81, 2.17) 1.30 (0.78, 2.10) 0.30
non-response at least once vs optimal 1.99 (1.01, 3.63) 1.98 (1.00, 3.62) 0.03
missing at least once vs optimal 3.26 (1.65, 5.96) 3.60 (1.80, 6.65) <0.001
Pre-ART WHO disease stage
stage 2 1(ref) 1(ref) 0.8
stage 3 1.08 (0.61, 2.02) 1.02 (0.57, 1.91)
stage 4 1.48 (0.76, 2.92) 1.19 (0.60, 2.41)
Pre-ART CD4 cell count
0-49 1.69 (0.88, 3.51) 1.43 (0.72, 3.07)
50-99 1.27 (0.61, 2.77) 1.18 (0.55, 2.61)
100-149 1.07 (0.49, 2.41) 1.01 (0.45, 2.29)
150-199 1(ref) 1(ref) 0.6
Pre-ART Body mass index
<20 1.35 (0.82, 2.18) 1.31 (0.79, 2.14)
20-27 1(ref) 1(ref) 0.5
>27 1.37 (0.59, 2.79) 1.33 (0.57 ,2.77)
Age at ART initiation groups
18-35 1(ref) 1(ref) 0.9
35-50 0.84 (0.53, 1.35) 0.92 (0.57, 1.50)
50+ 0.89 (0.31, 2.09) 1.03 (0.35, 2.48)
Sex
Female vs Male 1.23 (0.76, 2.04) 1.31 (0.79, 2.22) 0.3
Time since ART initiation in years
≤2 1(ref) 1(ref) 0.06
2-3 0.37 (0.17, 0.73) 0.40 (0.18, 0.79)
3-4 0.57 (0.30, 1.04) 0.60 (0.31, 1.10)
4-5 0.49 (0.24, 0.93) 0.47 (0.23, 0.91)
>5 0.76 (0.34, 1.54) 0.65 (0.29, 1.34)
Adherence history is given by 4 time-dependent indicators with “optimal” adherence as a reference class.
Our main study findings are based on the association
between adherence in the 3-9 month preceding interval
and immediate risk of mortality. Preliminary investigation
suggested that nominal adherence behaviour in the imme-
diately preceding intervals was strongly subject to reverse
causality (ie sick patients do not attend visits), and hence
we did not include adherence at the immediately pre-
ceding intervals in our adherence history variable. Whilst
several other time intervals t − u, ..., t − v were consid-
ered, we presented results only for the period 3-9 months
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Table 3 Estimated unadjusted and adjusted odds ratios (OR) with 95 percent confident intervals for the risk of death
obtained from the dynamic logistic regressionmodel and based on 1482 individuals in the CDMgroup alive after the first
year of the follow-up
Unadjusted OR 95% CI Adjusted OR 95% CI P-value
Adherence history:
poor at least once vs optimal 2.14 (1.45, 3.14) 2.18 (1.47, 3.22) < 0.001
non-response at least once vs optimal 2.16 (1.29, 3.52) 2.09 (1.22, 3.40) < 0.001
missing at least once vs optimal 3.46 (2.07, 5.54) 3.65 (2.15, 5.92) 0.005
Pre-ART WHO disease stage
stage 2 1(ref) 1(ref) 0.51
stage 3 1.67 (0.99, 3.03) 1.39 (0.82, 2.55)
stage 4 1.61 (0.88, 3.08) 1.28 (0.68, 2.48)
Pre ART CD4 cell count
0-49 3.61 (1.88, 7.85) 3.43 (1.74, 7.62)
50-99 2.75 (1.36, 6.14) 2.62 (1.28, 5.90)
100-149 2.49 (1.20, 5.63) 2.45 (1.18, 5.57)
150-199 1(ref) 1(ref) 0.01
Pre-ART Body mass index
< 20 1.63 (1.12, 2.38) 1.33 (0.90, 1.96)
20-27 1(ref) 1(ref) 0.35
> 27 0.98 (0.43, 1.93) 1.07 (0.46 ,2.15)
Age at ART initiation groups
18-35 1(ref) 1(ref) 0.07
35-50 0.72 (0.49, 1.05) 0.83 (0.56, 1.24)
50+ 1.45 (0.74, 2.63) 1.74 (0.87, 3.21)
Sex
Female vs Male 0.62 (0.43, 0.90) 0.72 (0.49, 1.06) 0.10
Time since ART initiation in years
≤ 2 1(ref) 1(ref) 0.13
2-3 1.65 (0.98, 2.84) 1.66 (0.98, 2.86)
3-4 1.10 (0.61, 1.99) 1.10 (0.61, 1.98)
4-5 1.64 (0.96, 2.86) 1.56 (0.90, 2.74)
> 5 0.91 (0.38, 1.96) 0.80 (0.33, 1.73)
Adherence history is given by 4 time-dependent indicators with “optimal” adherence as a reference class.
before as the associations with mortality were generally
very similar across that time period. Other adherence
summaries could also have been considered eg ’poor at
least once in 6 months’, for example, could have been
replaced by ‘poor at least k times in u − v + 1 months’,
but having shown strong associations with the simplest
model formulation, additional complexity is unlikely to
have improved models substantially, and the popula-
tion attributable fraction (PAF) is unlikely to change
much.
Kiwuwa-Muyingo et al. BMC Infectious Diseases 2013, 13:395 Page 11 of 14
http://www.biomedcentral.com/1471-2334/13/395
1 2 3 4 5 6
0.
90
0.
92
0.
94
0.
96
0.
98
1.
00
Years on ART
Pr
op
or
tio
n 
su
rv
iv
in
g
survival with optimal adherence LCM 
survival with optimal adherence CDM
observed survival LCM
observed survival CDM
Figure 4 Estimated (weighted Kaplan-Maier) survival curves and estimated survival curves under optimal adherence in the
LCM and CDM groups.
The strongest adherence predictor of immediate mor-
tality was missing one or more visits in the 3-9 month
preceding interval, with a remarkably strong effect in
both monitoring groups. DART participants were pro-
vided with ART until their next scheduled clinic visit,
and so missing a visit typically represented running out
of drugs (with the exception of those on 12-weekly ART
re-fills in the latter part of the trial). Such interrup-
tions may lead to development of drug resistance [24],
which would promote virological failure and hence CD4
cell count failure, and hence increased risk of mortal-
ity. Alternatively, they could identify a group of patients
with poorer health-seeking behaviour; delays in seeking
healthcare could increase the risk of dying following any
morbid events. Actively seeking high risk patients who
have missed clinic appointments might have a significant
impact on mortality. There is an urgent need for more
studies on patients who missed clinic appointments, the
causes of such missed appointments, and the outcomes
experienced by these patients, especially in places where
laboratory monitoring is not available. Although not sta-
tistically significant, there was also a suggestion that being
randomised to STI may have increased the mortality risk
of CDM participants more than LCM participants. Inter-
estingly, no mortality difference was observed during the
randomised follow-up on STI vs CT (5 vs 4 deaths respec-
tively) and there was no evidence of interaction with
monitoring strategy during this time [21]. One possible
explanation is that STIs raised the risk of first-line ART
failure. So the later detection of first-line failure in CDM
could have led to STI being associated with increased
mortality risk in CDM but not LCM subsequently during
the trial. Similarly, other pre-ART factors, such as pre-
ART CD4 and older age, were also associated with ART
failure and with increased mortality risk in CDM, but not
LCM.
Several studies have assessed the impact of adher-
ence on mortality and report evidence of an association
between adherence and long-term mortality risk among
HIV infected individuals receiving ART. For example, Chi
et al reported a 1.7 fold increased risk of post 12 month
mortality in a large scale public sector HIV care pro-
gramme in Zambia in those with <80% drug possession
ratio (DPR) based on pharmacy refill [16]. Lima et al [17]
demonstrated a 3 fold increased risk of mortality for a
DPR adherence threshold of <95%; Nachega et al [25]
reported a 3 fold increased risk of mortality in a South
African private sector HIV care programme for pharmacy
claims adherence<80%. Like our study, most studies used
indirect methods of adherence assessment based on self-
reports, rather than electronic medication monitoring
which is expensive and intrusive, although provides qual-
itatively and quantitatively different information about
adherence behaviours [10]. One challenge in assessing the
association between adherence and mortality is that the
impact of poor adherence may also be associated with
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the length of follow up. Another challenge is that adher-
ence may be confounded with other lifestyle and health-
seeking behaviours which might also impact outcomes.
For example, a meta analysis of adherence to drug/placebo
showed reduced mortality associated with good adher-
ence to both active drug regimens and to placebo [26].
Thus participants with good adherence to study drugs
may also have better behaviours (eg diet, exercise) and
more regular follow-up which may affect their outcome.
Another challenge is assessing the time between poor
adherence and death, and that several other events may
happen during that time period, such as increased viral
load, lowered CD4 counts, changing drug regimes and
opportunistic infections. This analysis using dynamic
logistic regression model enabled us to assess the full
effect of adherence on mortality without confounding
from factors on the causal pathway. Nevertheless these
studies, and others assessing adherence-mortality rela-
tionship, demonstrate that adherence remains important
in reducing mortality risk among HIV infected individ-
uals. Our finding that missed visits (also a proxy for
the DPR since missing visits typically means running out
of drugs) are closely associated with higher longer-term
mortality risk, sets the stage for future studies to address
causal relationships between adherence and mortality but
more importantly, to quantify, for patients and policy
makers, the impact of taking drugs and/or missed visits.
A potential limitation of our study was that many
patients were on triple nucleoside reverse transcriptase
inhibitor (3NRTI) regimens which are no longer recom-
mended in WHO guidelines. However, previous analyses
of adherence during the first-year on ART found similar
associations between self-reported missing doses in the
last month and VL suppression [23] as found in those
receiving standard WHO-recommended regimens, sug-
gesting that results may well be generalizable. Further,
the typically lower level viral load suppression found with
3NRTI regimens might in fact lead to clearer associa-
tions between poor adherence and mortality over shorter
timescales than might be observed with more robust reg-
imens. Whilst our inclusion only of those surviving 48
weeks on ARTmight be considered a limitation, we would
rather regard it as an advantage, since factors influenc-
ing early mortality on ART are much more likely driven
by pre-ART experiences and analyses including both early
and late deaths may therefore dilute the impact of differ-
ences associated with adherence over the longer-term. As
with all observational analyses, we also make the assump-
tion of no unmeasured confounders. Our model is also
unable to address the role of time-dependent confound-
ing, eg from current CD4 count, which would require
the use of more sophisticated causal models. However,
as adherence to ART precedes immunological recovery,
our analysis adjusting only for baseline (pre-ART) factors
is still able to estimate the overall impact of adherence.
Another limitation was that we used self-reported mea-
surements of adherence, which generally overestimate
adherence [14] as they are subject to recall and/or social
desirability bias [27]. Nevertheless, many studies have
shown at least some association between self-reported
and electronically monitored adherence, and have also
shown associations between some self-reported measures
and viral load suppression, suggesting self report has
some clinical significance [4,15,24]. Self-report adher-
ence measures are also preferred in many clinical set-
tings for their simplicity and practical use. Whilst here
we used such a self-report measure, it was also most
strongly associated with viral load suppression in an ear-
lier DART study [23]. “Optimal” adherence levels (pro-
portion not missing a dose in the last month, ie >95%,
see Figure 2 and Figure 3) are similar to, or even higher
than, those reported by several other clinical trials (>80%)
[10]. Even if this measure overestimates true adher-
ence, it was nevertheless strongly associated with mor-
tality, indicating that the effect of true adherence would
likely be even greater if this could have been measured
using other more accurate adherence measures, such
as electronic monitoring devices such as MEMSCAPS.
Other summary adherence measures could be consid-
ered rather than a dichotomous adherence measure; our
study shares this limitation inherent in many studies try-
ing to explore explanatory factors that might translate
into clinical use within busy ART clinics. One strength
of our study is that we explicitly considered missing vis-
its and non-response as different types of behaviour to
reporting non-adherence - this also avoided the need to
make other assumptions about missing data.
Conclusions
In summary, we show that poor adherence to ART is asso-
ciated with increased mortality risk at the individual level,
and that the estimated proportions of deaths on long-
term ART that could be delayed at population level (by
eliminating non-optimal adherence) are similar to ben-
efits from CD4 cell count monitoring of ART and thus
high enough to warrant considerable efforts on interven-
tions to support and improve adherence at a programme
level, particularly for patients not being monitored using
CD4 counts or viral loads. Onemechanism through which
laboratory monitoring may improve outcomes appears
to be to mitigate some of the negative consequences of
poor adherence by identifying poor adherers earlier and
enabling interventions. Several past and recent studies
suggest that several effective interventions that improve
ART adherence exist [28-30]. However the effects are
small and also transient - there is no simple strategy
for intervention [31]. Given recent successes and failures
[32,33] of adherence-enhancing interventions, further
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research aimed at improving adherence (through refined
adherence intervention strategies and approaches to
assessing effectiveness of interventions), will be essen-
tial to fully realise the benefits of ART. In the mean-
time, simple procedures can measure adherence and poor
adherence has again clearly been shown to be associated
with mortality: lives gained from effective interventions to
improve adherence would be considerable. Actively seek-
ing high risk patients who miss clinic appointments might
have a significant impact onmortality or at least should be
studied rigorously.
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